NCT03158090 The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
| NCT ID | NCT03158090 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ginkgo Leaf Center for Rare Disorders |
| Condition | Acromegaly |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,965 participants |
| Start Date | 2017-12-15 |
| Primary Completion | 2050-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,965 participants in total. It began in 2017-12-15 with a primary completion date of 2050-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.
Eligibility Criteria
Inclusion Criteria: 1. Be able and willing to sign the informed consent form (ICF) 2. Male, female, age 18-75 years old (including 18 years old and 75 years old). 3. Compliance with acromegaly diagnostic criteria: * At least one laboratory or medical record shows that the patient is random GH ≥ 2.5 μg / L * At least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor Exclusion Criteria: 1. Ectopic secretion of GH or pituitary cancer 2. The patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue. 3. Have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study. 4. Be a patient who, in the judgement of the Investigator, would be inappropriate for enrollment in this study
Frequently Asked Questions
Who can join the NCT03158090 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Acromegaly. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03158090 currently recruiting?
Yes, NCT03158090 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ginkgo Leaf Center for Rare Disorders to inquire about joining.
Where is the NCT03158090 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT03158090 clinical trial?
NCT03158090 is sponsored by Ginkgo Leaf Center for Rare Disorders. The trial plans to enroll 1,965 participants.